These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23350232)

  • 1. [Anti-HIV nucleoside drugs: retrospective view at future].
    Kukhanova MK
    Mol Biol (Mosk); 2012; 46(6):860-73. PubMed ID: 23350232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral drugs.
    De Clercq E
    Curr Opin Pharmacol; 2010 Oct; 10(5):507-15. PubMed ID: 20471318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The history of antiretrovirals: key discoveries over the past 25 years.
    De Clercq E
    Rev Med Virol; 2009 Sep; 19(5):287-99. PubMed ID: 19714702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
    Reynolds C; de Koning CB; Pelly SC; van Otterlo WA; Bode ML
    Chem Soc Rev; 2012 Jul; 41(13):4657-70. PubMed ID: 22618809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 reverse transcriptase inhibitors.
    El Safadi Y; Vivet-Boudou V; Marquet R
    Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery and development of HIV therapy: the new challenges.
    Perno CF
    Ann Ist Super Sanita; 2011; 47(1):41-3. PubMed ID: 21430337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of mutations that confer resistance to nucleoside analogs and protease inhibitors in HIV-1-infected patients. Study Group on Resistance to Antiretroviral Agents].
    Martínez G; Sarría L; Campelo C; Merchán A; Cisterna R
    Rev Esp Quimioter; 1999 Dec; 12(4):317-24. PubMed ID: 10855010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside analogues in 2008.
    Warwick Z; Churchill D
    J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
    [No Abstract]   [Full Text] [Related]  

  • 14. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.
    Lange J
    Antivir Ther; 2001; 6 Suppl 3():45-54. PubMed ID: 11678472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of 4'-C-substituted nucleosides for the treatment of HIV-1.
    Hayakawa H; Kohgo S; Kitano K; Ashida N; Kodama E; Mitsuya H; Ohrui H
    Antivir Chem Chemother; 2004 Jul; 15(4):169-87. PubMed ID: 15457679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.